問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Tri-Service General Hospital (在職)

Division of Neurology

Division of Neurology

更新時間：2023-09-19

何宗翰
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

3Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

何宗翰

List

6Cases

2023-09-28 - 2025-10-30

Phase III

Completed
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ZAVEGEPANT INTRANASAL (IN) FOR THE ACUTE TREATMENT OF MIGRAINE IN ASIAN ADULTS

  • Condition/Disease

    Migraine

  • Test Drug

    Zavegepant

Participate Sites
4Sites

Not yet recruiting3Sites

Study ended1Sites

2021-05-20 - 2026-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting2Sites

Terminated3Sites

2022-12-01 - 2024-07-08

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2020-10-01 - 2022-08-14

Phase III

Interventional, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of eptinezumab for the preventive treatment of migraine in patients with a dual diagnosis of migraine and Medication Overuse Headache

  • Condition/Disease

    Migraine,Medication Overuse Headache

  • Test Drug

    Eptinezumab

Participate Sites
3Sites

Recruiting3Sites

2020-12-15 - 2022-06-30

Phase III

A Phase 3, multi-center, randomized, double-blind, parallel-group, placebo-controlled clinical trial to evaluate the efficacy and safety of sodium oligomannate (GV-971) in treatment of mild to moderate Alzheimer’s disease (GREEN MEMORY: GREen Valley 971 EvaluatioN Memory)

  • Condition/Disease

    Alzheimer’s disease

  • Test Drug

    GV-971

Participate Sites
3Sites

Not yet recruiting1Sites

Recruiting1Sites

Terminated1Sites

2019-09-01 - 2022-07-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting4Sites

Terminated1Sites

聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB